Studies assessing the prognostic value of CRC subgroups, based on combinations of frequently occurring mutations (RAS, BRAF, PIK3CA) and/or MMR status, are very limited and rarely evaluate all markers at the same time.40, 41, 42, 43. This evidence concerns the gene BRAF and colorectal carcinoma.